Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 64

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 64
---
. Prior to this he was in the business services group at Robertson Stephens, an investment banking firm, from 1997 to 1998 and served as a strategy consultant in the energy group at Andersen Consulting (now known as Accenture plc) from 1991 to 1993. Mr. Patel served on the Board of Visitors of Duke University School of Law from 2011 to 2023 where he was a Senior Lecturing Fellow. Mr. Patel received a Juris Doctor with honors and Master of Business Administration from Duke University and Bachelor of Arts in Philosophy and Economics from Trinity University. Mr. Patel was selected to serve on our board of directors based on his extensive investment, leadership and operational experience. There are no family relationships between our board of directors and any of our executive officers. The principal occupation and employment during the past five years of each of our directors was carried on, in each case except as specifically identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our directors and any other person or persons pursuant to which he or she is to be selected as a director. There are no material legal proceedings to which any of our directors, executive officers or affiliates is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or our subsidiaries. Executive Officers Who Are Not Directors The following table identifies our current executive officers who are not directors, and sets forth their current positions at CERo Therapeutics, Inc. and their ages as of May1, 2025:

| Name                   |     | Age |     | Title                     |     | Officer Since |
| Executive Officers:    |     |     |     |                           |     |               |
| Andrew “Al” Kucharchuk |     |  44 |     | Chief Financial Officer   |     |          2024 |
| Kristen Pierce, Ph.D.  |     |  55 |     | Chief Development Officer |     |          2024 |

Andrew “Al” Kucharchukhas served as the Chief Financial Officer since October 2024. Mr.Kucharchuk has led initiatives in senior positions of corporate leadership and/or as a board member of publicly traded life science companies, including as Chief Financial Officer of Chain Bridge I (NASDAQ: CBRGU) since April 2024 and, previously, as the Chief Financial Officer of Nukkleus Inc. (NUKK) from